Dr. Stanley Mathew shares his professional opinion nerve blocking antibodies.

1. CURTIN HEALTHCARE SERVICES
Nerve Blocking
Antibodies
Dr. Stanley Mathew

2. It may surprise some people to learn that chronic lower
back pain is one of the main reasons that people seek
medical care about the world. Chronic pain like this has, in
part, lead to an increase in prescription painkillers. Thanks
to a push from the pharmaceutical industry, we're now in
the middle of an opioid epidemic despite conflicting
reports of the efficacy of opioids on pain. However, there
may be new solutions to pain without the risk of
dependence.
A recent study out of the University of Rochester Medical
Center (URMC) shows that a nerve-blocker known as
Tanezumab can effectively deal with back pain. The
medication, which has previously been tested as a
potential solution for knee and hip pain due to
osteoarthritis, is delivered just once every 60 days beneath
the patient's skin. The results are of the study, which was
held in eight countries around the world, are promising;
patients experienced less severe pain thanks to just a
single dose of the drug.

3. Researchers have already discovered that some proteins in
the blood can increase a person's sensitivity to pain,
making it feel more severe. Scientists focused on a specific
protein called nerve growth factor or NFG when developing
Tanezumab. The drug inhibits NFG in patients, leading to
decreases in the severity of pain.
Study participants must all previously tried at least three
different forms of pain relief unsuccessfully, so the effect of
Tanezumab is especially significant. Those patients who
become dependent on opioids may have already tried
other means of pain management to no avail. And
research doesn't show that Tanezumab has negative side
effects like opioids or even NSAIDs such as ibuprofen,
which can cause GI issues and blood clots after longterm
use..

4. However, researchers are aware of the possible
complications that nerve-blockers can have on bone health
despite reducing pain levels, which is why patients with
moderate or severe cases of osteoarthritis were excluded
from this study. Blocking NGF has been associated with
joint problems in previous, smaller studies of the drug. Still,
Tanezumab may be a suitable pain solution for some
patients when other risks are too great.
The U.S. Food and Drug Administration is currently
reviewing Tanezumab as an alternative to opioid pain
remedies

5. DR.STANLEYMATHEW.COM